| Company Name: | Immucor, Incorporated | | Ticker Symbol: | BLUD | | | WWW Address: | www.immucor.com | | CEO: | Dr. Gioacchino De Chirico | | No. of Employees: | 729 | | Common Issue Type: | CS | | Business Description: | The Company develops, manufactures and sells a complete line of reagents and automated systems used by hospitals, clinical laboratories and blood banks in tests performed to detect and identify certain properties of human blood.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 19.08 |  -0.28 | 18.57 | 19.48 | 19.39 | 19.39 | 19.06 | 238646 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 1,337.5 | 70.1 | 0.75 | 1.07 | 0.00 | 17.9 | 0.0 | 29.20 - 11.24 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 19.36 | $ | | PE Ratio - LTM | 17.9 | |
| Market Capitalisation | 1,357.8 | mil |
| Latest Shares Outstanding | 70.1 | mil |
| Earnings pS (EPS) | 1.07 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 412,273 | $ |
| Effective Tax Rate | 34.9 | % |
| Float | 69.3 | mil |
| Float as % of Shares Outstanding | 98.8 | % |
| Foreign Sales | 63 | mil |
| Domestic Sales | 238 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27.60 | % |
| Research & Devlopment (R&D) as % of Revenue | 4.10 | % |
| Gross Profit Margin | 75.2 | % |
| EBITDA Margin | 43.5 | % |
| Pre-Tax Profit Margin | 38.5 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 16.4 | % |
| Return on Equity (ROE) | 19.3 | % |
| Return on Capital Invested (ROCI) | 19.3 | % |
| Current Ratio | 4.6 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 928.7 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 2.95 | $ |
| Cash pS | 2.17 | $ |
| Book-Value pS | 5.74 | $ |
| Tangible Book-Value pS | 3.49 | $ |
| Cash Flow pS | 1.31 | $ |
| Free Cash Flow pS | 1.04 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.37 | |
| Price/Tangible Book Ratio | 5.55 | |
| Price/Cash Flow | 14.8 | |
| Price/Free Cash Flow | 18.7 | |
| P/E as % of Industry Group | 80.0 | % |
| P/E as % of Sector Segment | 10.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 3.1 | 102 | 4,364 | 6,628 |
| 4 Weeks | 19.39 | 17.75 | 17.88 | 8.3 | 101 | 4,985 | 84,749 |
| 13 Weeks | 19.39 | 16.84 | 18.27 | 6.0 | 99 | 5,804 | 354,029 |
| 26 Weeks | 19.39 | 11.24 | 15.05 | 28.6 | 107 | 8,305 | 1,038,108 |
| 52 Weeks | 29.20 | 11.24 | 24.27 | -20.2 | 65 | 9,279 | 2,310,424 |
| YTD | 29.20 | 11.24 | - | -27.2 | 59 | 9,688 | 2,199,276 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 18.98 | 18.82 | 18.27 | 16.89 | 18.58 | 0.75 | 0.66 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 19.80 | 97.8 | 14.77 |
| Income | 37.00 | 89.3 | 15.92 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 60.25 | NA | 93.42 |
| R&D | 21.95 | NA | 28.89 |
| Normalized Inc. | 36.01 | NA | 12.64 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 13.5 | 13.5 | 15.1 |
| Earnings % | 5.3 | 6.9 | 6.6 |
| EPS % | 7.1 | 7.1 | 7.0 |
| EPS $ | 0.02 | 0.02 | 0.07 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 42.66 |
| Current Ratio | 4.7 |
| Quick Ratio (Acid Test) | 3.7 |
| Liquidity Ratio (Cash) | 2.61 |
| Receivables Turnover | 5.5 |
| Average Collection Period | 65 |
| Working Capital/Equity | 50.1 |
| Working Capital pS | 2.73 |
| Cash-Flow pS | 1.27 |
| Free Cash-Flow pS | -0.52 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 14.51 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 14.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 3.8 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 468.9 |
| Interest/Capital Invested | 0.06 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.06 |
| Tobin's Q Ratio | 3.01 |
| Current P/E Ratio - LTM | 17.90 |
| Enterprise Value (EV)/EBITDA | 9.89 |
| Enterprise Value (EV)/Free Cash Flow | -41.43 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 5.55 |
| Price/Book Ratio - LTM | 3.37 |
| Price/Cash Flow Ratio | 14.8 |
| Price/Free Cash Flow Ratio - LTM | 18.7 |
| Price/Sales Ratio | 4.37 |
| P/E Ratio (1 month ago) - LTM | 16.7 |
| P/E Ratio (26 weeks ago) - LTM | 14.5 |
| P/E Ratio (52 weeks ago) - LTM | 23.6 |
| 5-Y High P/E Ratio | 70.7 |
| 5-Y Low P/E Ratio | 12.9 |
| 5-Y Average P/E Ratio | 35.6 |
| Current P/E Ratio as % of 5-Y Average P/E | 50 |
| P/E as % of Industry Group | 80.0 |
| P/E as % of Sector Segment | 10.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 17.9 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.74 |
| Tangible Book Value pS - LTM | 3.49 |
| Book Value pS - LTM | 5.74 |
| Capital Invested pS | 5.48 |
| Cash pS - LTM | 2.17 |
| Cash Flow pS - LTM | 1.31 |
| Free Cash Flow pS - LTM | 1.04 |
| Earnings pS (EPS) | 1.07 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -12.22 |
| Free Cash Flow Margin 5YEAR AVG | 16.27 |
| Net Profit Margin | 25.3 |
| Net Profit Margin - 5YEAR AVRG. | 24.4 |
| Equity Productivity | 0.78 |
| Return on Equity (ROE) | 19.8 |
| Return on Equity (ROE) - 5YEAR AVRG. | 23.1 |
| Capital Invested Productivity | 0.78 |
| Return on Capital Invested (ROCI) | 19.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 23.1 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 16.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | 18.8 |
| Gross Profit Margin | 75.2 |
| Gross Profit Margin - 5YEAR AVRG. | 72.3 |
| EBITDA Margin - LTM | 43.5 |
| EBIT Margin - LTM | 38.6 |
| Pre-Tax Profit Margin | 38.9 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 38.1 |
| Effective Tax Rate | 34.9 |
| Effective Tax Rate - 5YEAR AVRG. | 36.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 237 |
| Revenue per Employee | 412,273 |
| Net Income per Employee | 104,503 |
| Average Collection Period | 68 |
| Receivables Turnover | 5.5 |
| Day's Inventory Turnover Ratio | 169 |
| Inventory Turnover | 2.1 |
| Inventory/Sales | 12.7 |
| Accounts Payble/Sales | 3.11 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 1.56 |
| Fixed Assets Turnover | 1.46 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 2.20 |
| Revenue per $ Plant | 6.92 |
| Revenue per $ Common Equity | 0.78 |
| Revenue per $ Capital Invested | 0.78 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 27.7 |
| Research & Devlopment (R&D) as % of Revenue | 3.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 3.6 |
|
|  
|
| |
 |  |